Fluorescent hiPSC-derived MYH6-mScarlet cardiomyocytes for real-time tracking, imaging, and cardiotoxicity assays.


Journal

Cell biology and toxicology
ISSN: 1573-6822
Titre abrégé: Cell Biol Toxicol
Pays: Switzerland
ID NLM: 8506639

Informations de publication

Date de publication:
02 2023
Historique:
received: 08 04 2022
accepted: 29 06 2022
medline: 29 3 2023
pubmed: 24 7 2022
entrez: 23 7 2022
Statut: ppublish

Résumé

Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) hold great potential in the cardiovascular field for human disease modeling, drug development, and regenerative medicine. However, multiple hurdles still exist for the effective utilization of hiPSC-CMs as a human-based experimental platform that can be an alternative to the current animal models. To further expand their potential as a research tool and bridge the translational gap, we have generated a cardiac-specific hiPSC reporter line that differentiates into fluorescent CMs using CRISPR-Cas9 genome editing technology. The CMs illuminated with the mScarlet fluorescence enable their non-invasive continuous tracking and functional cellular phenotyping, offering a real-time 2D/3D imaging platform. Utilizing the reporter CMs, we developed an imaging-based cardiotoxicity screening system that can monitor distinct drug-induced structural toxicity and CM viability in real time. The reporter fluorescence enabled visualization of sarcomeric disarray and displayed a drug dose-dependent decrease in its fluorescence. The study also has demonstrated the reporter CMs as a biomaterial cytocompatibility analysis tool that can monitor dynamic cell behavior and maturity of hiPSC-CMs cultured in various biomaterial scaffolds. This versatile cardiac imaging tool that enables real time tracking and high-resolution imaging of CMs has significant potential in disease modeling, drug screening, and toxicology testing.

Identifiants

pubmed: 35870039
doi: 10.1007/s10565-022-09742-0
pii: 10.1007/s10565-022-09742-0
pmc: PMC10042918
doi:

Substances chimiques

MYH6 protein, human 0
Myosin Heavy Chains EC 3.6.4.1
Cardiac Myosins EC 3.6.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

145-163

Informations de copyright

© 2022. The Author(s).

Références

Cell Death Dis. 2011 Dec 22;2:e244
pubmed: 22190003
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Sci Rep. 2021 Feb 4;11(1):3026
pubmed: 33542270
ACS Appl Mater Interfaces. 2017 Jan 11;9(1):224-235
pubmed: 27936534
Exp Cell Res. 2009 Nov 15;315(19):3406-18
pubmed: 19769963
iScience. 2022 Mar 25;25(4):104153
pubmed: 35434558
Stem Cell Reports. 2017 Dec 12;9(6):1765-1779
pubmed: 29173897
Nat Rev Cardiol. 2020 Jun;17(6):341-359
pubmed: 32015528
Mater Sci Eng C Mater Biol Appl. 2019 Jun;99:905-918
pubmed: 30889765
ACS Appl Mater Interfaces. 2019 Jun 12;11(23):20589-20602
pubmed: 31120238
Biomaterials. 2016 Aug;98:64-78
pubmed: 27179434
Methods Enzymol. 2014;546:119-38
pubmed: 25398338
Dis Model Mech. 2012 Mar;5(2):220-30
pubmed: 22052944
Circ Res. 2020 Apr 10;126(8):1086-1106
pubmed: 32271675
Cardiovasc Res. 1998 Apr;38(1):25-53
pubmed: 9683906
Stem Cells. 2016 Jan;34(1):13-26
pubmed: 26446349
Circ Res. 2018 Jul 6;123(2):132-137
pubmed: 29976683
Stem Cells Int. 2016;2016:1684792
pubmed: 27057166
Biology (Basel). 2020 Nov 16;9(11):
pubmed: 33207727
EBioMedicine. 2017 Feb;16:30-40
pubmed: 28169191
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Sci Transl Med. 2017 Feb 15;9(377):
pubmed: 28202772
Front Bioeng Biotechnol. 2020 May 27;8:455
pubmed: 32528940
Nat Methods. 2011 Oct 23;8(12):1037-40
pubmed: 22020065
Cardiovasc Res. 2020 Mar 1;116(3):658-670
pubmed: 31173076
Cell. 2006 Dec 15;127(6):1151-65
pubmed: 17123592
Cell Stem Cell. 2019 May 2;24(5):802-811.e5
pubmed: 30880024
Nat Methods. 2017 Jan;14(1):53-56
pubmed: 27869816
PLoS One. 2015 May 13;10(5):e0126596
pubmed: 25970162
Stem Cell Res Ther. 2014 Jan 21;5(1):12
pubmed: 24444355
Stem Cells. 2015 Jan;33(1):56-67
pubmed: 25187301
PLoS One. 2012;7(10):e48659
pubmed: 23119085
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Curr Protoc Hum Genet. 2018 Jan 24;96:21.11.1-21.11.20
pubmed: 29364519
Int J Mol Sci. 2022 Mar 16;23(6):
pubmed: 35328619
Front Pharmacol. 2021 Feb 18;12:607364
pubmed: 33679396
Stem Cell Res Ther. 2020 Mar 26;11(1):138
pubmed: 32216837
Materials (Basel). 2019 Jun 03;12(11):
pubmed: 31163704
Lab Chip. 2016 Feb 7;16(3):599-610
pubmed: 26758922
Annu Rev Physiol. 2010;72:19-44
pubmed: 20148665
J Cell Biochem. 2019 Oct;120(10):16681-16691
pubmed: 31090105
PLoS One. 2011 Jan 04;6(1):e16004
pubmed: 21245908
Science. 2013 Feb 15;339(6121):823-6
pubmed: 23287722
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):E1848-57
pubmed: 22645348
Front Bioeng Biotechnol. 2020 Dec 14;8:597661
pubmed: 33381498
J Tissue Eng Regen Med. 2009 Mar;3(3):196-207
pubmed: 19235264

Auteurs

Reeja Maria Cherian (R)

Heart Group, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. reeja.maria.cherian@tuni.fi.

Chandra Prajapati (C)

Heart Group, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Kirsi Penttinen (K)

Heart Group, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Martta Häkli (M)

Heart Group, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Janne T Koivisto (JT)

Biomaterials and Tissue Engineering Group, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

Mari Pekkanen-Mattila (M)

Heart Group, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Katriina Aalto-Setälä (K)

Heart Group, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. katriina.aalto-setala@tuni.fi.
Heart Hospital, Tampere University Hospital, Tampere, Finland. katriina.aalto-setala@tuni.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH